COVID-19: Mayo Clinic is committed to taking care of our patients, learners and staff as we address the COVID-19 situation. Learn more about COVID-19 online education, resources, and live course cancellations through June 30, 2020.

Mayo Clinic Proceedings - Chronic Lymphocytic Leukemia: Diagnosis and Treatment (May 1, 2018)

One of the premier peer-reviewed clinical journals in general and internal medicine, Mayo Clinic Proceedings is among the most widely read and highly cited scientific publications for physicians, with a circulation of approximately 125,000. Mayo Clinic Proceedings is published by Elsevier and sponsored by Mayo Clinic and the Mayo Foundation for Medical Education and Research. The mission of Mayo Clinic Proceedings is to promote the best interest of patients by advancing the knowledge and professionalism of the physician community. Since 2009 the Journal has offered CME credit for specific articles from both the Mayo Clinic for Concise Review for Clinicians and specially commissioned Symposia articles (comprehensive coverage on one topic).  

Participation in this activity consists of reviewing articles and responding to a short online test. It is estimated that this activity will take approximately one hour per article.  There is no charge for participating in this Journal CME activity.

To receive CME credit, please do the following:

  • Click Take Course
  • Complete quiz and evaluation (There is a required 80% pass rate in order to earn credit, with 1 retake allowed.)
  • Print your Record of Attendance


Questions?  cme@mayo.edu

 

Target Audience

The target audience for Mayo Clinic Proceedings is primarily internal medicine physicians and other clinicians who wish to advance their current knowledge of clinical medicine and who wish to stay abreast of advances in medical research.

Learning Objectives

On completion of this article, you should be able to: (1) correctly formulate a diagnosis of chronic lymphocytic leukemia (CLL); (2) evaluate prognostic factors for patients with CLL; and (3) understand the indications for treatment for patients with CLL and identify the most appropriate regimens in the frontline and relapse settings.

Course summary
Available credit: 
  • 1.00 ABIM
  • 1.00 AMA PRA Category 1 Credit
Course opens: 
05/01/2018
Course expires: 
04/30/2020
Disclosure Summary 

As a Jointly Accredited Provider by ACCME, ACPE, and ANCC, Mayo Clinic College of Medicine and Science must ensure balance, independence, objectivity and scientific rigor in its educational activities. Course Director(s), Planning Committee Members, Faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty also will disclose any off label and/or investigational use of pharmaceuticals or instruments discussed in their presentation. Disclosure of these relevant financial relationships will be published in activity materials so those participants in the activity may formulate their own judgments regarding the presentation.

Listed below are individuals with control of the content of this program who have disclosed…

No relevant financial relationships:

Planning Committee, Editorial Board Members and Staff
Thomas J. Beckman, M.D.
Terry Jopke
Manish Kohli, M.D.
Michelle Mauermann, M.D.
James F. Meschia, M.D.
Karl A. Nath, M.D.
Jenna Pederson
S. Vincent Rajkumar, M.D.
Kimberly D. Sankey
Joseph I. Sirven, M.D.
Margaret (Peg) Wentz
Christopher M. Wittich, M.D.


Relevant financial relationships: None.

Off-label drugs:  None.

AUTHORS DISCLOSURE SUMMARY: 

Authors:  Paolo Strati, MD; Nitin Jain, MD; and Susan O’Brien, MD

Affiliations: Division of Cancer Medicine (P.S.) and Department of Leukemia (N.J.), University of Texas  MD Anderson Cancer Center, Houston, TX; and Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, CA (S.O.).

 

Conflicts of Interest: Dr O’Brien has been a consultant for Pharmacyclics LLC, Vaniam Group LLC, Amgen Inc, Celegene Corporation, Alexion Pharmaceuticals  Inc, Gilead Sciences Inc, Pfizer Inc, GlaxoSmithKline plc, Sunesis Pharmaceuticals Inc, Astellas Pharma Inc, TG Therapeutics Inc, Janssen Pharmaceuticals  Inc, Aptose Biosciences, and AbbVie Inc; she has received honoraria and research support and funding from Pharmacyclics LLC, Ascerta Pharma, Gilead Sciences Inc, ProNAi Therapeutics Inc, Regeneron  Pharmaceuticals Inc, and TG Therapeutics, Inc; she has received research funding from Pfizer Inc; and she has been a member of the Board of Directors/advisory committees of the CLL Global Research Foundation. Dr. Jain is a consultant for Pharmacyclics, Abbvie, and Verastem; received honoraria from Pharmacyclics, Abbvie, and Verastem; and received grant/research support from  Pharmacyclics, Abbvie, Genentech, Verastem, and BMS.

Off-label drugs:  Manufacturer(s)/Provider(s): Pharmacyclics, Abbvie

Product(s)/Device(s): Ibrutinib, Venetoclax

Accreditation Statement:


In support of improving patient care, Mayo Clinic College of Medicine and Science is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

 

Credit Statement(s):

AMA

Mayo Clinic College of Medicine and Science designates this journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


ABIM
Successful completion of this CME activity enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

Participation information will be shared with ABIM through PARS. 

Other Healthcare Professionals

A certificate of attendance will be provided to other healthcare professionals for requesting credits in accordance with state nursing boards, specialty societies, or other professional associations.

For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s), please go here.

Available Credit

  • 1.00 ABIM
  • 1.00 AMA PRA Category 1 Credit

Accreditation Period

Course opens: 
05/01/2018
Course expires: 
04/30/2020
Please login or create an account to take this course.

Cancellation and Refund Policy:

Request for cancellations must be submitted in writing to cme@mayo.edu. When cancelling a registration for a course 14 days or more before the course start date, a full refund (minus a $75 administrative fee) will be issued in the same form of payment the registration was received. No refunds are granted less than 14 days before the course start date.

Any use of this site constitutes your agreement to the Terms and Conditions of Online Registration.